GlassScriptPhysician profile
Rakesh Gulati
NPI 1770571937
$656,742.95
in general payments reported to CMS, 2019-2025
20 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $57K · 2021: $71K · 2022: $93K · 2023: $117K · 2024: $102K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $273K · Consulting Fee: $15K · Travel and Lodging: $12K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $272,551.00 |
| Consulting Fee | $15,195.95 |
| Travel and Lodging | $12,398.27 |
| Food and Beverage | $10,990.52 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383,682.52 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $70,476.35 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $52,999.85 | 2019-2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $45,634.78 | 2019-2020 | |
| Travere Therapeutics, INC. | $39,441.92 | 2024-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $26,859.21 | 2020-2025 | |
| Aurinia Pharma U.S., INC. | $17,191.01 | 2021-2024 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $6,325.00 | 2019 | |
| Calliditas Therapeutics US INC. | $4,627.03 | 2024-2025 | Tarpeyo |
| Sobi, INC | $2,353.64 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,336.87 | 2020 | |
| Vifor Pharma, INC. | $2,100.00 | 2020 | |
| Horizon Therapeutics Plc | $2,041.00 | 2019-2021 | |
| Medtronic, INC. | $216.50 | 2023 | Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $144.18 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $120.00 | 2024 | |
| Lilly USA, LLC | $107.62 | 2023 | Mounjaro |
| Nxstage Medical, INC. | $63.41 | 2022-2025 | Nxstage System One, Nxstage Pureflow Solution, Pureflow Sl |
| Apellis Pharmaceuticals, INC. | $22.06 | 2025 | Empaveli |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.